James Lynam

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie, Joshua D. Cohen, Kamel Lahouel et al. · New England Journal of Medicine · 2022 · 976 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial

Jeanne Tie, Yuxuan Wang, Jonathan M. Loree et al. · Nature Medicine · 2025 · 39 citations

Medicine, Oncology, Gastrointestinal Oncology +16

TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol

Jarad Martin, Paul Keall, Shankar Siva et al. · BMJ Open · 2019 · 30 citations · Full text

Medicine, Oncology, Radiation Oncology +17